NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "YmAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced its management team will participate in the following upcoming investor conferences: Wedbush PacGrow Healthcare Conference Date: Tuesday, August 13, 2024 Location: New York, NY Format: Investo ...

NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "YmAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced its management team will participate in the following upcoming investor conferences: Wedbush PacGrow Healthcare Conference Date: Tuesday, August 13, 2024 Location: New York, NY Format: Investo ...

Core Points - The United States District Court for the Southern District of New York has approved a proposed class action settlement for purchasers of Y-mAbs Therapeutics, Inc. stock between October 6, 2020, and October 28, 2022, totaling $19,650,000 [1][8][10] - The settlement aims to resolve allegations that the defendants made material misrepresentations regarding Y-mAbs product candidate omburtamab, which the defendants deny [10] Settlement Class Details - The Settlement Class includes all persons or entities who purchased or acquired Y-mAbs stock during the specified period, with certain exclusions such as defendants and their affiliates [2][5] - Members of the Settlement Class must submit a Proof of Claim and Release Form by October 7, 2024, to be eligible for distribution from the Net Settlement Fund [11] Hearing Information - A hearing is scheduled for October 28, 2024, to determine the fairness of the proposed settlement, the allocation plan, and the attorneys' fees request [8][10] - The Lead Counsel may request up to one-third (33 1/3%) of the settlement amount as attorneys' fees, along with reimbursement of expenses not exceeding $200,000 [8]

NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "YmAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Peter Pfreundschuh as Chief Financial Officer, effective June 28, 2024. Mr. Pfreundschuh will report to Mike Rossi, President and Chief Executive Officer. Mr. Pfreundschuh p ...

Company Overview - Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing novel radioimmunotherapy and antibody-based therapeutic products for cancer treatment [7][9] - The company's product pipeline includes DANYELZA® (naxitamab-gqgk), the first FDA-approved treatment for relapsed or refractory high-risk neuroblastoma [9] Leadership Appointment - Peter Pfreundschuh has been appointed as Chief Financial Officer, effective June 28, 2024, and will report to Mike Rossi, President and CEO [7][11] - Pfreundschuh has extensive experience in the healthcare sector, having previously served as CFO at Voyager Therapeutics and held executive roles at several other biopharmaceutical companies [8][11] Strategic Positioning - The company is at a critical inflection point, gaining U.S. commercial traction with DANYELZA® while advancing its Self-Assembly DisAssembly Pretargeted Radioimmunotherapy (SADA-PRIT) technology platform [11] - The leadership believes that with the new CFO, the company is well-positioned to make strategic decisions that will enhance its mission of improving patient lives [11]

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q1 2024 Earnings Conference Call May 8, 2024 8:00 AM ET Company Participants Courtney Dugan - Head-Investor Relations Michael Rossi - President and Chief Executive Officer Bo Kruse - Chief Financial Officer Sue Smith - Chief Commercial Officer Vignesh Rajah - Chief Medical Officer Conference Call Participants Alec Stranahan - Bank of America Bill Maughan - Canaccord Genuity Nick Unan - BMO Capital Markets David Nierengarten - Wedbush Securities Operator Good morning, ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38650 (Address of principal executive offices) (Zip Code) (646)-885-8505 (Registrant's telephone number, including area c ...

Exhibit 99.1 Y-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate Developments New York, NY, May 7, 2024 (GLOBE NEWSWIRE) – Y-mAbs Therapeutics, Inc. (the "Company" or "Y- mAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and, antibody-based therapeutic products for the treatment of cancer, today reported financial results for the first quarter ended March 31, 2024. "We continued to make meanin ...

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2023 Earnings Conference Call March 1, 2024 8:00 AM ET Company Participants Courtney Dugan - Vice President, Head of Investor Relations Michael Rossi - President and Chief Executive Officer Sue Smith - Chief Commercial Officer Vignesh Rajah - Chief Medical Officer Bo Kruse - Chief Financial Officer Conference Call Participants Alec Stranahan - Bank of America David Nierengarten - Wedbush Securities Lukas Shumway - BMO Capital Markets Operator Good morning and welco ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38650 Y-mAbs Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 47-4619612 (State ...